M Stanley Ratings and TPs on China Biotech Stocks
I'm LongbridgeAI, I can summarize articles.M Stanley has provided ratings and target prices for several China biotech stocks. Keymed Bio-B (Overweight, TP: 97), Innovent Bio (Overweight, TP: 135), and DualityBio-B (Overweight, TP: 493) saw significant price increases. Hutchmed's rating was adjusted from Underweight to Equalweight (TP: 21.3). Other stocks like Remegen and InnoCare received Equalweight ratings with target prices adjusted to 98 and 17, respectively.
Shares | Ratings | Target prices (HK$)
KEYMED BIO-B(02162.HK) +4.400 (+7.593%) Short selling $14.33M; Ratio 17.162% | Overweight | 93.5 -> 97
INNOVENT BIO(01801.HK) +8.650 (+11.556%) Short selling $276.41M; Ratio 19.410% | Overweight | 130 -> 135
LEADS BIOLABS-B(09887.HK) +0.900 (+1.479%) Short selling $549.67K; Ratio 5.201% | Equalweight | 59 -> 62
HUTCHMED(00013.HK) +0.490 (+2.754%) Short selling $5.61M; Ratio 11.319% | Underweight -> Equalweight | 21.4 -> 21.3
REMEGEN(09995.HK) +4.150 (+5.256%) Short selling $16.50M; Ratio 8.949% | Equalweight | 89 -> 98
INNOCARE(09969.HK) +0.460 (+4.100%) Short selling $8.23M; Ratio 16.150% | Equalweight -> Overweight | 19.6 -> 17
DUALITYBIO-B(09606.HK) +17.200 (+8.222%) Short selling $8.42M; Ratio 6.536% | Overweight | 493
ABBISKO-B(02256.HK) +0.160 (+1.670%) Short selling $1.47M; Ratio 21.819% | Overweight | 22
ZAI LAB(09688.HK) +0.390 (+2.863%) Short selling $49.75M; Ratio 39.140% | Overweight | 19
VISEN PHARMA-B(02561.HK) -0.180 (-0.803%) Short selling $8.80K; Ratio 1.964% | Overweight | 50
EVEREST MED(01952.HK) +1.400 (+4.871%) Short selling $5.29M; Ratio 9.764% | Equalweight | 40
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 12:25.)